GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » Debt-to-Revenue

Acarix AB (OSTO:ACARIX) Debt-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Acarix AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Acarix AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Acarix AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr6.21 Mil. Acarix AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.


Acarix AB Debt-to-Revenue Historical Data

The historical data trend for Acarix AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB Debt-to-Revenue Chart

Acarix AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.63 0.14 0.04 -

Acarix AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 - -

Competitive Comparison of Acarix AB's Debt-to-Revenue

For the Medical Devices subindustry, Acarix AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acarix AB's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Acarix AB's Debt-to-Revenue falls into.



Acarix AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Acarix AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Acarix AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Acarix AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acarix AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acarix AB (OSTO:ACARIX) Business Description

Traded in Other Exchanges
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines